First test for stem-cell institute -- money
By Jesse Reynolds,
San Francisco Chronicle
| 05. 15. 2005
Funding mechanism must avoid conflict of interest
The authors of last November's successful Proposition 71, the stem- cell research initiative, asked California voters to trust them in two distinct ways.
First, they convinced voters -- in some cases with shamelessly exaggerated promises about the imminence and likelihood of cures -- to invest $3 billion in research that has potential but is still at an early stage.
The second request was written into the initiative in print so fine that few voters had a chance of understanding it. Using obscure legalese, the initiative exempted the state agency it created, the California Institute for Regenerative Medicine, from many of the hard-won legal protections meant to ensure effective and transparent state governance. The result is that the institute, an agency entirely funded by the California public, is being run according to the practices of private enterprise. It best resembles a publicly funded, privately managed venture capital firm.
Now this experiment is facing a major obstacle. Lawsuits are challenging the constitutionality of Prop. 71's exclusion of public and legislative oversight. The state attorney general has determined that the bonds to fund...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...